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Summary
 
In hepatocellular carcinoma (HCC), autoantibodies to intracellular antigens are detected in
30–40% of patients. Patients with chronic hepatitis or liver cirrhosis develop HCC, and when
this occurs, some patients exhibit autoantibodies of new specificities. It has been suggested that
these novel autoantibody responses may be immune system reactions to proteins involved in
transformation-associated cellular events. One HCC serum shown to contain antibodies to un-
identified cellular antigens was used to immunoscreen a cDNA expression library, and a full
length cDNA clone was isolated with an open reading frame encoding 556 amino acids with a
predicted molecular mass of 62 kD. The 62-kD protein contained two types of RNA-binding
motifs, the consensus sequence RNA–binding domain (CS-RBD) and four hnRNP K homol-
ogy (KH) domains. This protein, provisionally called p62, has close identity (66–70%) to three
other proteins at the amino acid sequence level, and all four proteins may belong to a family
having CS-RBD in the NH
 
2
 
-terminal region and four KH domains in the mid-to-COOH–
terminal region. The homologous proteins are: KH domain–containing protein overexpressed
in cancer (Koc); zipcode binding protein, a protein which binds to a conserved nucleotide ele-
ment in chicken 
 
b
 
-actin mRNA (ZBP1); and a protein which binds to a promoter cis element
in 
 
Xenopus laevis
 
 TFIIIA gene (B3). p62 protein is cytoplasmic in location, and autoantibodies
were found in 21% of a cohort of HCC patients. Patients with chronic hepatitis and liver
cirrhosis, conditions which are frequent precursors to HCC, were negative for these autoanti-
bodies, suggesting that the immune response might be related to cellular events leading to
transformation. However, the possible involvement of p62 autoantigen as a factor in the trans-
formation process remains to be elucidated.
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A
 
utoantibodies against intracellular antigens are com-
monly found in a number of systemic autoimmune
diseases (1, 2) and have been used to screen cDNA expres-
sion libraries to isolate cDNA clones encoding target au-
toantigens. Such studies have revealed that many autoanti-
gens are components of subcellular particles involved in
important cell functions such as DNA replication (3, 4),
DNA transcription (5–7), RNA processing (8), and cell di-
vision (9–11). Studies of autoimmune diseases such as sys-
temic lupus erythematosus have shown that the autoanti-
body responses in the majority of if not all patients are
targeted at multiple components present within subcellular
particles. It has been well documented that autoantibodies
such as anti-Sm in systemic lupus erythematosus may target
several proteins in such particles, including the A, B/B
 
9
 
, C,
D, and 70-kD proteins, all of which are components of
small nuclear ribonucleoprotein complexes (8). These and
other observations have led to the hypothesis that an anti-
gen-driven mechanism underlies the production of these
autoantibodies (12–14) and that certain intracellular parti-
cles or their components become immunogenic because of
dysregulation of their function or alterations in molecular
structure or localization, leading to the provocation of an
immune response (1, 12).
Autoantibodies have been described in cancer patients,
including patients with leukemia, malignant melanoma,
lung, breast, gastrointestinal, gynecological, nasopharyngeal,
and prostate cancer, paraneoplastic neurological syndromes,
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hepatocellular carcinomas, and a variety of other neoplasms
(15–30). On the premise that identification of the autoanti-
gens might provide some information regarding intracellu-
lar molecules possibly engaged in the transformation process,
this laboratory has focused on hepatocellular carcinoma
(HCC)
 
1
 
 as the subject of investigation. This interest is re-
lated to the observation that in certain patients with HCC,
novel autoantibody responses appeared coincident with or
sometimes immediately before the clinical detection of
HCC (23, 24). These observations were made possible by
the availability of serial samples of stored sera from patients
with chronic hepatitis and liver cirrhosis, two precursor
conditions to HCC; HCC eventually occurs in 
 
z
 
30–40%
of these patients. One previously identified nuclear antigen,
HCC1, is a nuclear protein with structural motifs found in
the serine–arginine family of alternative splicing factors (25).
Another antigen targeted by autoantibodies is a DNA-
binding nuclear antigen called SG2NA, a protein highly
expressed in the S and G2 phases of the cell cycle (26). In
this study, an HCC serum that contained autoantibodies to
a 62-kD cellular protein was used to immunoscreen a T24
 
l
 
zap cDNA expression library. A novel cytoplasmic auto-
antigen named p62 was identified. p62 is a putative RNA-
binding protein, and antibodies to p62 were detected in 21%
of a cohort of HCC patients from Henan Province, Peo-
ple’s Republic of China.
 
Materials and Methods
 
Sera and Antibodies.
 
HCC sera were obtained from 95 sub-
jects included in an epidemiological study previously described
and were from Henan Province, People’s Republic of China
(31). Sera from 77 patients with liver diseases (26 asymptomatic
HBsAg carriers, 31 patients with acute hepatitis, and 20 patients
with chronic hepatitis and liver cirrhosis), and 30 normal human
sera, all from the same province, were available for these studies.
All of the above sera came from the Sanitary and Anti-Epidemic
Station (Henan Province). 40 normal human sera from the San
Diego, CA area were also included as controls. Human prototype
sera containing autoantibodies to previously identified intracellu-
lar antigens were from patients with systemic autoimmune dis-
eases (2) and obtained from the serum bank of the Autoimmune
Diseases Center of The Scripps Research Institute (La Jolla, CA).
 
Cell Culture and Cell Extracts.
 
MOLT-4 (human acute lym-
phoblastic leukemia), T24 (human transitional cell bladder carci-
noma), HEp-2 (human epidermoid laryngeal carcinoma), HeLa
(human epitheloid cervical carcinoma), HepG2 (human hepato-
cellular carcinoma), A549 (human lung carcinoma), and 3T3
(mouse fibroblast) cell lines were obtained from the American
Type Culture Collection and cultured following the specific pro-
tocol for each cell line. Cells grown in monolayers were solubi-
lized directly in Laemmli’s sample buffer containing protease in-
hibitors (Boehringer Mannheim). Solubilized lysates were briefly
sonicated before electrophoresis on SDS–polyacrylamide gels.
 
Immunofluorescence Studies.
 
Initial identification of autoanti-
 
bodies in sera was performed using methanol- and acetone-fixed
commercial HEp-2 cell slides (Bion Enterprises, Ltd.). The find-
ings were usually confirmed in other experiments using T24,
HepG2, and 3T3 cells that were grown on coverslips, fixed for
5 min at 
 
2
 
20
 
8
 
C in 100% methanol, and permeabilized for 3 min
at 
 
2
 
20
 
8
 
C in 100% acetone. As a second antibody, FITC-conju-
gated goat anti–human IgG (Caltag Laboratories) was applied. A
titer of 
 
.
 
1:40 dilution was interpreted as positive.
 
Western Blotting.
 
Western blotting was performed essentially
as described by Chan and Pollard (32). Cell extracts were electro-
phoresed on SDS-PAGE and transferred to nitrocellulose paper.
After preblocking with PBS containing 0.5% Tween-20 and 5%
nonfat milk for 30 min at room temperature, the nitrocellulose
strips were incubated for 60 min at room temperature with a 1:100
dilution of serum. As secondary antibody, horseradish peroxi-
dase–conjugated goat anti–human IgG (Caltag Laboratories) was
applied (1:2,000 dilution). The detection of immunoreactive
bands was performed with an ECL kit (Amersham Corp.) ac-
cording to the manufacturer’s instructions and followed by auto-
radiography.
 
T24 and HeLa Cell Labeling and Immunoprecipitation.
 
T24 and
HeLa cells were cultured and radiolabeled with [
 
35
 
S]methionine.
For preparation of T24 and HeLa cell extracts, cells were col-
lected by centrifugation, combined with two times packed cell
volume buffer A (10 mM Tris-HCl, pH 7.5; 150 mM NaCl, 1.5
mM MgCl
 
2
 
, and 0.5% NP-40), and held on ice for 10 min to
allow cell lysis. The supernatant obtained by centrifugation at
10,000 
 
g
 
 for 10 min at 4
 
8
 
C was used as antigen preparation in im-
munoprecipitation studies. Before immunoprecipitation, labeled cell
extracts were precleared by adding 100 
 
m
 
l 10% protein A–Seph-
arose stock/ml extract, mixed for 5 min on ice, and centrifuged
to collect supernatant. Typically, 100 
 
m
 
l 10% protein A–Seph-
arose, 500 
 
m
 
l buffer B (50 mM Tris-HCl, pH 7.4; 150 mM
NaCl; 5 mM EDTA; 0.5% NP-40; 0.5% deoxycholic acid; 0.1%
SDS; and 0.02% sodium azide) containing BSA at 10 
 
m
 
l (stock:
10 mg/ml), 40 
 
m
 
l labeled cell extract, 10 
 
m
 
l serum, and 10 
 
m
 
l pro-
tease inhibitor (Boehringer Mannheim) was added to a standard
immunoprecipitation reaction. After incubation for 1 h, the im-
munoprecipitated beads were washed five times with 1 ml buf-
fer B. Finally, the beads were eluted with an equal volume of 2
 
3
 
Laemmli’s sample buffer and analyzed in SDS-PAGE followed by
autoradiography.
 
cDNA Cloning, 5
 
9
 
 Rapid Amplification of cDNA Ends (RACE)
and Sequence Analysis.
 
HCC serum YZ was diluted 1:100 and
used for screening a T24 
 
l
 
zap cDNA expression library. Before
screening of the cDNA library, the serum was extensively absorbed
against bacteria infected with wild-type 
 
l
 
zap phage (33). The pre-
absorbed serum was used to immunoscreen 3.0 
 
3
 
 10
 
5
 
 recombinant
plaques using 
 
125
 
I-labeled goat anti–human IgG as the secondary de-
tecting reagent. Screening was carried out on duplicate filters, and
one double-positive clone, JY1, was isolated and subcloned in vivo
into pBK-CMV plasmid using ExAssist helper phage (Stratagene
Inc.) as recommended in the manufacturer’s instructions. The clone
JY1 was amplified, purified, and used for sequence analysis. cDNA
insert was analyzed by restriction mapping and sequencing. The
clone JY1 was a partial sequence, and RACE methodology was
used to obtain overlapping 5
 
9
 
 clones using the Marathon-Ready
cDNA from human colorectal adenocarcinoma SW480 cell line
(Clontech). Nucleotide sequence was determined in both strands
using a semiautomated sequencer from Applied Biosystems (model
373). Oligonucleotide primers were synthesized with a DNA syn-
thesizer (Applied Biosystems; model 394). DNA and protein se-
quences were analyzed by the Genetics Computer Group Sequence
 
1
 
Abbreviations used in this paper:
 
 CS-RBD, consensus sequence RNA–
binding domain; HCC, hepatocellular carcinoma; KH, K homology;
ORF, open reading frame; RACE, rapid amplification of cDNA ends;
RT, reverse transcriptase. 
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Analysis Software Package for UNIX computers (version 7.4; 34).
Alignment of protein sequences was achieved with a Multiple
Alignment Program (http://dot.imgen.bcm.tmc.edu:9331/multi-
align/multi-align.html; reference 35).
 
Reverse Transcription (RT)-PCR and Confirmation of p62 Open
Reading Frame (ORF).
 
The ORF of p62 was reamplified and
confirmed by RT-PCR using T24 cell mRNA as template. One
set of sense and antisense primers was designed, and their posi-
tions with respect to the p62 full length cDNA are indicated (see
Fig. 2 A): rt3 sense, 5
 
9
 
-TTGAATTCGCCATGGTGAACAAG-
CTTTACATCGGGAACC-3
 
9
 
 and rt4 antisense, 5
 
9
 
-TTTATGT-
CGACGGTGTTGGAAGGGCTACATT-3
 
9
 
, incorporating an
EcoRI and SalI site, respectively. RT-PCR was performed using
the one-tube method as described by Pfeffer et al. (36). In brief,
1 
 
m
 
l T24 mRNA (0.5 
 
m
 
g/
 
m
 
l), 10 
 
m
 
M primer (1 
 
m
 
l each), 1.25 U
Taq polymerase (GIBCO BRL), 100 U SuperScript II RNase
H–reverse transcriptase (GIBCO BRL), 20 U RNase inhibitor
(Promega Corp.), 0.25 
 
m
 
l of 10 
 
m
 
M dNTPs, and 2.5 
 
m
 
l 10
 
3
 
PCR buffer containing 500 mM KCl; 100 mM Tris-HCl, pH
8.3; 15 mM MgCl
 
2
 
; and 0.1% gelatin were added to a final total
volume of 25 
 
m
 
l, and the PCR steps were programmed using a
thermocycler (Eppendorf). The reactions were performed at
50
 
8
 
C for 1 h and followed by 30 cycles at 57
 
8
 
C for 10 s, 72
 
8
 
C for
2 min, and 94
 
8
 
C for 10 s. RT-PCR products were analyzed by
agarose gel electrophoresis.
 
Purification of Recombinant Protein.
 
For increased expression
and purification of recombinant protein, p62 cDNA derived
from RT-PCR was subcloned into the EcoRI and SalI sites of
pET28a vector, which provides the NH
 
2
 
-terminal fusion protein
with 6
 
3
 
 histidine and T7 epitope tags. The recombinant protein
was overexpressed in 
 
Escherichia coli
 
 BL21 (DE3) and purified us-
ing nickel column chromatography. The protocol used for the
high-level expression and purification of 6
 
3
 
 histidine–tagged pro-
teins was performed as described (Qiagen, Inc.). Elution buffer
(8 M urea, 0.1 M NaH
 
2
 
PO
 
4
 
, and 0.01 M Tris, pH 4.5) was used
to elute the recombinant protein.
 
In Vitro Transcription and Translation.
 
The p62 cDNA was
transcribed and translated in vitro using TnT-coupled reticulocyte
lysate system (Promega Corp.) in the presence of [
 
35
 
S]methionine
(ICN) as described (Promega Biotec). Labeled products were used
as substrates for immunoprecipitation analysis.
 
Affinity Purification of Antibodies.
 
Recombinant protein was
electrophoresed on 15% SDS-PAGE and transferred to nitrocellu-
lose membranes. The membranes were cut into strips and the re-
combinant protein bands confirmed by Western blotting. Nitro-
cellulose strips were incubated with diluted serum at 1:100, and
unbound antibodies were removed by washing with PBS contain-
ing 0.5% Tween-20 before elution of bound antibodies with 0.5
ml elution buffer (200 mM KH
 
2
 
PO
 
4
 
, 150 mM NaCl, and 0.1%
BSA, pH 2.5). Affinity-purified antibodies were immediately neu-
tralized by the addition of 1 M Tris-HCl, pH 8.7. The antibodies
were concentrated with Centricon-30 microconcentrators (Ami-
con Corp.), and different dilutions (1:5, 1:25, and 1:50) were used
for immunofluorescence assay and Western blotting analysis.
 
Rabbit Immunization.
 
Four female New Zealand White rab-
bits were immunized by subcutaneous injections of 0.5 mg of
p62 recombinant protein in complete Freund’s adjuvant. Rabbits
were boosted two times with 0.5 mg p62 recombinant protein in
incomplete Freund’s adjuvant at 1-mo intervals, and blood was
collected 10 d after the last booster injection.
 
Northern Blotting.
 
Nylon membranes blotted with poly A
 
1
 
RNA isolated from multiple human tissues and several human
cancer cell lines were obtained from Clontech. An antisense ribo-
probe was generated from a 480-bp fragment corresponding to
the NH
 
2
 
-terminal domain of p62 (see Fig. 2 A) and labeled with
[
 
a
 
-
 
32
 
P]UTP (Clontech) as described. In brief, the membranes
were hybridized with 
 
32
 
P-labeled p62 riboprobe for 2 h at 74
 
8
 
C,
washed in 2
 
3
 
 SSC and 0.1% SDS at 74
 
8
 
C for 20 min and in
0.1
 
3
 
 SSC and 0.1% SDS at 65
 
8
 
C for 20 min, and exposed to
x-ray film for 4 h at 
 
2
 
70
 
8
 
C. A 2.0-kb human 
 
b
 
-actin cDNA
provided by Clontech was used as control probe.
 
ELISA.
 
Standard protocol for ELISA was used as described
by Rubin (37). Purified p62 recombinant proteins were diluted
in PBS to a final concentration of 1 
 
m
 
g/ml for coating Immulon
2 microtiter plates (Dynatech Laboratories). Human sera diluted
1:100 were incubated in the antigen-coated wells. Horseradish
peroxidase–conjugated goat anti–human IgG (Caltag Laborato-
ries) and the substrate 2.2
 
9
 
-azinobis (3-ethylbenzthiazoline sul-
fonic acid; Boehringer Mannheim) were used as detecting re-
agents. Each sample was tested in duplicate, and the average OD
at 490 nm was used for data analysis. The cutoff value designating
positive reaction was the mean OD of normal sera 
 
1
 
 3 SD.
 
Results
 
Detection of Autoantibody against Cytoplasmic Antigen p62.
 
Initial studies focused on the analysis of serum specimens
from 95 HCC patients from Henan Province. Many of
these sera contained antibodies reactive with a 62-kD cel-
lular antigen that was present in low concentration in
MOLT-4 cell extracts but in higher concentration in ex-
tracts from other cell lines. Fig. 1 shows Western blotting
of three such sera against whole cell extracts from MOLT-4,
T24, and HepG2. Lanes 1, 5, and 9 are normal human se-
rum showing negative reactions. Lanes 2, 6, and 10 show
the reactivities of HCC serum YZ. This serum showed
Figure 1. Reactivity of three HCC sera in Western blotting against
whole cell extracts from MOLT-4, T24, and HepG2 cell lines. Lanes 1, 5,
and 9 were normal human sera. Serum YZ (lanes 2, 6, and 10) showed
strong reactivity with a 90-kD protein in MOLT-4 cells and reacted
weakly with a 62-kD protein in MOLT-4 cells and T24 cell extracts. A
strong reaction with the 62-kD protein was detected with HepG2 cell ex-
tracts, together with a strong reaction with a 50-kD protein. Sera YL
(lanes 3, 7, and 11) and CH (lanes 4, 8, and 12) demonstrate other types of
reactions (see text). These representative data demonstrate that HCC sera
are heterogeneous in their antibody repertoires and that different cell lines
apparently have different expressions of 90-, 62-, and 50-kD proteins. 
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strong reactivity with a 90-kD band in MOLT-4 cell ex-
tracts and weak reaction with a 62-kD band. With T24 cell
extract, the 62-kD band was slightly stronger, but in
HepG2 cell extract the 62-kD reactivity was as strong or
stronger than the 90-kD reactivity. In addition, a good sig-
nal was observed at 50 kD. Serum YL from a different pa-
tient contained antibodies primarily against the 90-kD anti-
gen and displayed very weak reactivity with the 62-kD
antigen (lanes 3, 7, and 11). A third serum, CH, appeared
to have antibodies primarily against the 62- and 50-kD an-
tigens (lanes 4, 8, and 12). In addition, serum CH, as well
as YZ, demonstrated weak reactivity with other antigens of
higher and lower molecular sizes, but the predominant re-
activities detected were against the 90-, 62-, and 50-kD
proteins. These data demonstrated that different cell lines
showed different levels of expression of these intracellular
proteins, with T24 expressing higher levels of the 62-kD
and HepG2 expressing higher levels of both 62- and 50-kD
antigens than MOLT-4.
 
cDNA Cloning of the 62-kD Autoantigen.
 
The above data
suggested that in order to isolate cDNA clones encoding
the 62-kD antigen, T24 or HepG2 cDNA expression li-
braries would be the preferred cell lines. HCC serum YZ
was used to immunoscreen a T24 
 
l
 
zap cDNA expression
library. One positive clone was isolated from 3.0 
 
3
 
 10
 
5
 
recombinant plaques, purified to homogeneity, and sub-
cloned in vivo into pBK-CMV. This clone, designated
JY1, was a cDNA of 3.3 kb and was shown to have an ap-
parent coding sequence with a termination codon and a
long 3
 
9
 
 UTR with a poly A tail. 5
 
9
 
-RACE methodology
was used to obtain overlapping 5
 
9
 
 clones using the Mara-
thon-Ready cDNA repertoire derived from human col-
orectal adenocarcinoma SW480 cell line. Two overlapping
independent clones were obtained and analyzed, with the
longest clone, H27, containing a cDNA insert of 374 bp.
An in-frame TGA stop codon at position 320 bp upstream
of a methionine start codon was found. The presumptive
full length cDNA is shown in Fig. 2 C. The cDNA has a
5
 
9
 
-UTR of 435 bp, an ORF of 1,668 bp, and a 3
 
9
 
-UTR of
1,564 bp. RT-PCR was performed using T24 cell line
Figure 2. Full length cDNA
and corresponding protein se-
quence of p62. (A) Serum YZ
was used to immunoscreen a T24
lzap cDNA library, and a partial
cDNA clone designated JY1
with an insert of 3.3 kb was iso-
lated. Using 59-RACE method-
ology, a further cDNA clone 59
to JY1, named H27, was iso-
lated. The domain structure of
p62 with the NH2-terminal con-
sensus RNA–binding domain
and four KH domains is shown.
(B) RT-PCR was performed us-
ing T24 cell line RNA. A 1.7-kb
isolate was obtained consistent
with the size of the putative ORF
of p62. (C) The nucleotide and
deduced amino acid sequence of
p62 is shown. The CS-RBD lo-
cated in the NH2-terminal re-
gion and four KH domains ex-
tending from the middle region
to the COOH-terminal region
are underlined. p62 cDNA con-
tains 3,667 bp, and the ORF
has 556 amino acids. Two poly-
adenylation sequences in the
39-untranslated region are under-
lined. The cDNA sequence has
been submitted to GenBank un-
der accession number AF057352.1105 Zhang et al.
RNA as template with one pair of designed primers (rt3
and rt4, shown in Fig. 2 A). The RT-PCR products were
of z1.7 kb, compatible with the size of the ORF in the
isolated cDNA clone (Fig. 2 B). The ORF codes for 556
amino acids with a predicted molecular mass of 62 kD and
a calculated pI of 8.59.
p62 Has RNA-binding Motifs and Is Highly Homologous to
Three Other RNA-binding Proteins. The 62-kD protein
contained two types of RNA binding motifs, the consen-
sus sequence RNA–binding domain (CS-RBD) and four
hnRNP K homology (KH) domains (38). The CS-RBD
domain was located in the NH2-terminal region, and the
four KH domains extended from the middle region to
the COOH-terminal region (Fig. 2). Three proteins were
found to have high degrees of homology to p62 at both
nucleotide and protein levels. Table I compares percent
similarity and identity of p62 with the other three proteins.
KH domain–containing protein overexpressed in cancer
(Koc), a putative oncogene (39), had 66.5% identity and
80.3% similarity to p62. Zipcode binding protein (ZBP1), a
b-actin mRNA-binding protein in chicken (40), had a
70.5% identity and 83.9% similarity to p62, and B3 (X. laevis
TFIIIA–binding protein), an oocyte factor that binds to a
developmentally regulated cis element in the TFIIIA gene
(41), showed 69.7% identity and 82.7% similarity to p62.
Table I also shows that other KH domain–containing pro-
teins such as FMR1 (42), hnRNP K (43), and hnRNP X
(44) showed much lower levels of homology. The sequences
of p62, Koc, ZBP1, and B3 are shown in Fig. 3 A, demon-
strating the CS-RBD and four hnRNP K homology domains.
Table I. Similarity and Identity of p62 and Related Proteins and Other KH Domain–containing Proteins
Similarity (Identity)
Koc ZBP1 B3 FMR1 hnRNP K hnRNP X
%
p62 80.3 (66.5) 83.9 (70.5) 82.7 (69.7) 39.8 (16.2) 48.0 (25.7) 41.5 (17.4)
Koc 83.1 (75.6) 90.3 (84.1)
ZBP1 89.0 (78.7)
Percent identity and similarity of homologous protein sequences were calculated using GAP program (Genetics Computer Group). Koc, KH do-
main–containing protein overexpressed in cancer; ZBP1, b-actin mRNA zipcode–binding protein; B3, Xenopus laevis KH domain–containing tran-
scription factor B3; FMR1, the fragile X mental retardation gene; hnRNP K, heterogeneous nuclear ribonucleoprotein K protein; hnRNP X, het-
erogeneous nuclear ribonucleoprotein X protein.
Figure 3. Similarity between p62 and three
RNA-binding motif proteins Koc, ZBP1, and B3.
(A) The identity between p62 and the other three
proteins are shown (*). (B) The great similarity of
the domain structures is shown. The RNA-binding
domains with two conserved RNP regions, RNP1
and RNP2, and four KH domains are boxed. A
nine–amino acid sequence (VGAIIGKE/KG) of
unknown function in the first three KH domains is
shown in bold as is the REV-like nuclear export
signal in the second KH domain.1106 p62 Cytoplasmic Cancer Antigen
In addition, a nine–amino acid sequence (VGAIIGKE/KG) of
unknown function previously reported in ZBP1 (40) was also
found in the first three KH domains of the other three pro-
teins. A potential REV-like nuclear export signal also found
in ZBP1 protein (40) was present in position 308–319 of
p62. The sequence alignments of the four proteins are de-
picted in Fig. 3 A, and their domain structures are shown
in Fig. 3 B.
Recombinant p62 Protein Was Recognized by Human Auto-
antibodies and Comigrated with Cellular 62-kD Protein. The
p62 recombinant protein was expressed using the pET28a
vector in E. coli and purified using nickel affinity column
chromatography. A 62-kD polypeptide was detected by
Coomassie blue staining together with one prominent
lower molecular mass product (Fig. 4 A, lane 1). HCC sera
containing antibodies to the 62-kD cellular antigen reacted
strongly with the 62-kD recombinant protein and also with
the lower molecular weight product (Fig. 4 A, lane 3). In
contrast, HCC sera containing only 90-kD autoantibodies
such as serum YL and normal human serum (Fig. 4, lane 2)
were nonreactive. In vitro–translated products of p62
cDNA showed that the polypeptide migrated at 62-kD
(Fig. 4 B, lane 6) and was immunoprecipitated by human
anti-p62 prototype serum (Fig. 4 B, lane 4) but not normal
human serum (Fig. 4 B, lane 5). The in vitro–translated
products (Fig. 4 C, lane 8) comigrated with the 62-kD an-
tigen detected by Western blotting of HepG2 cell extract
(Fig. 4 C, lane 8a).
Immunization with p62 Recombinant Protein. To further
confirm that the recombinant protein was identical to the
62-kD cellular protein, four female New Zealand White
rabbits were immunized with p62 recombinant protein.
Rabbit immune sera immunoprecipitated in vitro–trans-
lated products (Fig. 5 A, lane 3). In addition, Fig. 5 B shows
that the cellular 62-kD protein was immunoprecipitated by
immune rabbit serum (lane 10) in a fashion similar to hu-
man anti-p62 prototype sera (lanes 7 and 8), using extracts
from [35S]methionine–labeled HeLa cells as the antigen prep-
aration. Immune rabbit sera were also reactive in Western
blotting with 62-kD proteins from T24, HepG2, and A549
cells (data not shown). Fig. 5 B shows that other proteins
were also immunoprecipitated, but many of these were also
immunoprecipitated by preimmune rabbit serum and normal
human sera and are presumed to be nonspecific precipitates.
Subcellular Localization of p62 Protein. It had been previ-
ously observed by immunofluorescent histochemistry that
HCC sera with antibodies to the 62-kD antigen were neg-
ative for staining of the nucleus but positive for cytoplasmic
staining. Immune rabbit antiserum affinity-purified from
recombinant protein showed cytoplasmic staining, as de-
picted in Fig. 6 B. The pattern of human HCC prototype
serum YZ is shown in Fig. 6 A. The fine details of cyto-
plasmic staining of human serum YZ and rabbit immune
sera are somewhat different, with rabbit serum showing a
coarser pattern of cytoplasmic staining than human serum.
This could be related to the fact that human sera are poly-
clonal and might contain other autoantibodies. The rele-
vant finding was that both human HCC sera with anti–p62-
kD antigen reactivity and rabbit immune sera were reactive
with antigens that were cytoplasmic in location.
p62 mRNA Expression in Tissues and Cell Lines. Using
a 480-bp fragment corresponding to the COOH-terminal
Figure 4. p62 recombinant protein expressed as a 63 histidine tag pro-
tein in E. coli was purified using nickel column chromatography. (A) Mo-
lecular mass markers (lane M). A 62-kD peptide that corresponded to the
size of the ORF of p62 was detected in SDS-PAGE with Coomassie blue
staining (lane 1). HCC serum YZ, which was used for cDNA cloning,
was reactive with p62 recombinant protein in Western blot analysis (lane
3), but the recombinant protein was not reactive with normal human se-
rum (lane 2) or HCC sera that did not contain detectable antibodies to the
62-kD protein (not shown). A lower molecular size product, presumably
a degradation product, detectable by Coomassie blue staining was also re-
active with HCC serum (lanes 1 and 3). (B) Immunoprecipitation of in
vitro–translated p62 cDNA. Anti-p62 prototype serum (lane 4), normal
human serum (lane 5), and in vitro–translated products alone (lane 6). (C)
Comigration of the in vitro–translated products of p62 with the 62-kD
cellular protein in HepG2 cells. The panel (lanes 7–9) was processed by
autoradiography and the same panel (7a–9a) used subsequently for West-
ern blot analysis. Lanes 7/7a contained HepG2 cell extracts alone, lanes
8/8a contained a mixture of in vitro–translated radiolabeled products and
HepG2 cell extracts, and lanes 9/9a contained in vitro–translated radiola-
beled products alone. The in vitro–translated radiolabeled product of p62
cDNA comigrated exactly with cellular p62.
Figure 5. Human anti–62-kD antibody and rabbit anti–recombinant
p62 antibodies recognize recombinant antigen. (A) Immunoprecipitation
using in vitro–translated products of p62. Lane 1, in vitro–translated
products; lane 2, preimmune rabbit serum (No. 3366); lane 3, immune
rabbit serum (No. 3366). (B) Immunoprecipitation using [35S]methio-
nine–labeled HeLa cell extracts. Lane 4, normal human serum; lane 5,
anti-SSB/La prototype serum, which recognizes an irrelevant 48-kD au-
toantigen used as a positive control for the assay; lane 6, HCC serum with-
out p62 autoantibodies; lanes 7 and 8, p62 prototype sera; lane 9, preim-
mune rabbit serum (No. 3366); lane 10, immune rabbit serum (No. 3366).1107 Zhang et al.
domain of p62 as probe (Fig. 2 A), two major forms of p62
transcripts were detected in Northern blotting using com-
mercially available poly A1 RNA from a number of human
tissues and cell lines. Fig. 7 demonstrates that there was a
3.7-kb transcript (lower arrow) that was reactive with the
probe, as well as a 5.2-kb transcript (upper arrow). The
3.7-kb transcript of p62 was found in heart and placenta,
whereas brain, lung, liver, kidney and pancreas gave much
lower signals or were negative for p62 expression. A signal
for skeletal muscle migrated somewhat more slowly than
the 3.7-kb transcript (see data showing the probe corre-
sponding to the NH2-terminal domain below). High levels
of the 3.7-kb transcript were also detected in HeLa, K-562
(chronic myelogenous leukemia), SW480 (colorectal adeno-
carcinoma), A549 (lung carcinoma), and G361 (melanoma)
cell lines, whereas low expression was observed in HL60
(promyelocytic leukemia), MOLT-4 (lymphoblastic leuke-
mia), and Raji (Burkitt’s lymphoma) cell lines. The pres-
ence of the 3.7-kb transcript in these cell lines showed
good correlation with the presence of a 62-kD polypeptide
antigen in extracts of these cell lines, whereas cell lines
negative for the 3.7-kb transcript contained negligible or
barely detectable amounts of 62-kD polypeptide. The data
are not shown for all cell lines, but as can be seen in Fig. 1,
MOLT-4 cell extracts contained low levels of p62 antigen
and low levels of 3.7-kb transcript (Fig. 7 B). The North-
ern blot data just described were confirmed with an anti-
sense riboprobe generated from a 687-bp fragment corre-
sponding to the NH2-terminal domain of p62, and the
same membrane shown in Fig. 7 A was stripped and rehy-
bridized with this probe. The 3.7- and 5.2-kb transcripts
were specifically detected by this probe, a result similar to
the observations shown in Fig. 7 A with the exception that
the “slower” 3.7-kb band in skeletal muscle was not de-
tected. From these observations, we propose that both the
3.7- and 5.2-kb transcripts represent cellular mRNAs en-
coding the 62-kD protein. The identity of the 5.2-kb tran-
script has not been determined, but it could represent an
alternative mRNA for the 62-kD protein with extra 59 up-
stream or 39 untranslated sequences.
Analysis of Sera from Humans with Different Conditions. An
enzyme-linked immunosorbent assay system was developed
using p62 recombinant protein as antigen and a total of 242
sera from humans with different conditions were examined
for reactivity. Table II shows that detectable antibodies to
p62 antigen were present in 21.1% of patients in a group of
patients with HCC from Henan Province. However, in sera
from patients with conditions that are known to be precursor
diseases to HCC, including asymptomatic HBsAg, acute
Figure 6. p62 is a cytoplasmic protein, as revealed by immunofluores-
cence analysis of HEp-2 cell substrate using human p62 prototype serum
YZ (A) and affinity-purified rabbit anti–p62 serum No. 3366 (B).
Figure 7. Northern blot analysis of p62 mRNA. The nylon membrane
blotted with poly A1 RNA isolated from multiple human tissues (A) and
human cancer cell lines (B) was purchased from Clontech. Each lane con-
tained 2 mg of purified poly A1 RNA. An antisense riboprobe was gener-
ated from the 480-bp fragments corresponding to the COOH-terminal
domain of p62 (see Fig. 2 A) and hybridized to the membrane at a con-
centration of 1.0 3 106 cpm of the probe per milliliter of hybridization
solution. Two transcripts of 3.7 and 5.2 kb were detected in human tis-
sues (A, arrows) and cancer cell lines (B, arrows). The 3.7-kb transcript of
p62 was found in heart and placenta, but its occurrence was lower or neg-
ative in brain, lung, liver, kidney, and pancreas. A signal for skeletal mus-
cle migrated somewhat more slowly than the 3.7-kb transcript (see text).
High levels of the 3.7-kb transcript were detected in HeLa, K-562,
SW480, A549, and G361 cell lines, but low expression was observed in
HL-60, MOLT-4, and Raji cell lines. The 3.7-kb transcript expression
corresponded to detectable cellular p62 protein (see text), but the signifi-
cance of the 5.2-kb RNA is unknown. A 2.0-kb human b-actin cDNA
probe was used as a control for monitoring RNA levels. As described in
the manufacturer’s (Clontech) instructions, there are two forms of b-actin
mRNA, a 2- and 1.6–1.8-kb form, in heart and skeletal muscle.
Table II. Prevalence of p62 Autoantibody in Human Sera from 
Henan Province by ELISA Screening
Categories
Prevalence
patients with p62 antibody/
total patients with disease
Hepatocellular carcinoma 20/95 (21.1%)
Asymptomatic HBsAg carrier 0/26
Acute hepatitis 0/31
Chronic hepatitis 0/20
Normal human sera 0/30
Normal human sera* 0/40
*This group of sera was derived from the San Diego area.1108 p62 Cytoplasmic Cancer Antigen
hepatitis, and chronic hepatitis, no antibodies to p62 were de-
tected. Normal human sera from patients who came from
Henan Province or the San Diego area were also negative
for p62 antibodies.
Discussion
Study of human tumor antigens recognized by the autol-
ogous host has had a long history, and T cell–recognized
epitopes on human tumor cells have been extensively char-
acterized (30). However, antibody-defined tumor antigens
have been receiving greater attention recently, and several
centers have used a method called SEREX (serological
analysis of recombinant cDNA expression libraries), librar-
ies of cDNA constructs made from mRNA extracted from
tumor tissue (29) and screening of such libraries with autol-
ogous serum. From these studies, several novel as well as
previously defined tumor antigens have been identified
(30). Our approach was not restricted to use of cDNA li-
braries from autologous tumors because our previous stud-
ies had shown that antibodies in HCC sera were reactive
with antigens expressed by a variety of tissue culture cell
lines (23–25). The autoantigens identified included some
previously recognized in autoimmune diseases such as lupus
and scleroderma (22, 23). However, an unusual feature in
the HCC model was that novel antigen-antibody reactions
were detected in some patients during transformation from
chronic liver disease to malignancy. Therefore, use of such
sera to isolate and identify antigens might reveal special sig-
natures of cancer cells. A novel protein with alternative
splicing factor motifs (25) and a cell cycle–related nuclear
protein with WD-40 motifs (26) have been isolated. These
novel autoantigens, including p62 reported here, are not
restricted to cancer cells but are also expressed in normal
cells, an observation which has also been reported for can-
cer antigens in melanoma. These antigens have been called
differentiation antigens (28). At this point, it is unclear why
some differentiation antigens become capable of provoking
autoimmune responses, but possibilities which have been
raised in the case of p53 include gene mutations, gene
product overexpression, and unusual complexes with other
cellular proteins such as heat shock proteins (27, 45).
In addition to the remarkably high percentage of similar-
ity and identity between p62 on the one hand and ZBP1
and Koc on the other, there are several features of these
proteins that are of interest. ZBP1 is a chicken protein of
68 kD which was identified through its property of binding to
a conserved element in the 39 untranslated region of b-actin
mRNA (40). Rabbit antibodies raised against ZBP1 poly-
peptides were shown to bind to b-actin mRNA in the
leading edge of the lamella in cells such as chicken embryo
fibroblasts and 3T3 fibroblasts (40). Studies are in progress
to determine whether recombinant p62 is capable of bind-
ing in vitro to the “zipcode” element of b-actin mRNA as
is the case with ZBP1.
The Koc protein was isolated following analysis of differ-
ential gene expression in pancreatic cancer tissue (39). High
transcript levels of Koc were found not only in pancreatic
cancer tissue but also in soft tissue sarcoma, gastric cancer,
and colon cancer. Differences in mRNA expression of Koc
in different tissues has been reported (39). We have also
observed different transcript levels of p62 in different tissues
and, in addition, high levels of expression of p62 transcript
in some cell lines (HeLa, K-562, SW480, A549, and G361)
but low expression in others including the promyelocytic
leukemia HL-60, lymphoblastic leukemia MOLT-4, and
Burkitt’s lymphoma Raji. It is perhaps of some interest that
the two human members (p62 and Koc) of this putative
family of RNA-binding proteins appear to be associated in
some way with cancer. It has recently been reported that
two different Koc-homologous genes were also identified
by SEREX methodology (46), but sequence information
concerning these genes and their relationship to cancer are
not yet available.
Previously, we reported that several patients with HCC
mount de novo immune responses to nuclear antigens at
the time of conversion from chronic hepatitis or liver cir-
rhosis to HCC (24) and that the autoantibodies that were
produced against intracellular antigens might be regarded
as immune system reporters of abnormal intracellular mo-
lecular events. Novel proteins that have been detected in-
clude HCC1 (25), a putative member of the SR family of
alternative splicing factors, and SG2NA, a protein highly
expressed in the S and G2 phases of the cell cycle (26). p62
appears to be another such molecule, but unlike the anti-
body responses to HCC1 and SG2NA, which were observed
in individual patients, the autoimmune response to p62 was
detected in .20% of one group of HCC patients, suggest-
ing that a shared stimulus might be inciting the immune
responses. This shared stimulus could be environmental in
nature, but this is as yet only conjecture. An important
study that could not be performed at this time was the anal-
ysis of HCC tissues to determine whether there were ab-
normalities in the p62 gene or in its expression, as tissue
specimens were not available in this retrospective study.
This will be the focus of a prospective study in newly iden-
tified HCC patients with autoantibodies to p62.
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Note added in proof. While this paper was in press, an article by J. Nielsen et al. was published (Mol. Cell. Biol. 19:
1262–1270) describing a cDNA called IMP-2 (insulin-like growth factor II mRNA binding protein) that was
completely identical to p62 except for an insertion of 43 amino acids between the KH2 and KH3 domains.
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